6-Regioisomeric 5,8-quinolinediones as potent CDC25 inhibitors against colorectal cancers.

[1]  J. Ferlay,et al.  Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN , 2022, Gut.

[2]  Lu-jin Li,et al.  Whether Patients With Stage Ⅱ/Ⅲ Colorectal Cancer Benefit From Adjuvant Chemotherapy: A Modeling Analysis of Literature Aggregate Data , 2022, Frontiers in Pharmacology.

[3]  A. Matsuda,et al.  Recent advances in the treatment of colorectal cancer: A review. , 2022, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.

[4]  R. Tarkowski,et al.  Robotic-Assisted vs. Standard Laparoscopic Surgery for Rectal Cancer Resection: A Systematic Review and Meta-Analysis of 19,731 Patients , 2021, Cancers.

[5]  Changping Wu,et al.  The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer , 2021, Frontiers in Immunology.

[6]  Hamed Manoochehri,et al.  CDC25A is Strongly Associated with Colorectal Cancer Stem Cells and Poor Clinical Outcome of Patients , 2021, Gene Reports.

[7]  Pengfei Xu,et al.  Global colorectal cancer burden in 2020 and projections to 2040 , 2021, Translational oncology.

[8]  F. Bray,et al.  The ever‐increasing importance of cancer as a leading cause of premature death worldwide , 2021, Cancer.

[9]  A. Janecka,et al.  Synthesis and structure-activity relationship study of novel 3-diethoxyphosphorylfuroquinoline-4,9-diones with potent antitumor efficacy. , 2021, European journal of medicinal chemistry.

[10]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[11]  A. Desai,et al.  5-Fluorouracil Rechallenge After Cardiotoxicity , 2020, The American journal of case reports.

[12]  Jing-Yuan Fang,et al.  Comprehensive review of targeted therapy for colorectal cancer , 2020, Signal Transduction and Targeted Therapy.

[13]  D. Cunningham,et al.  Postoperative chemotherapy improves survival in patients with resected high‐risk Stage II colorectal cancer: results of a systematic review and meta‐analysis , 2020, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[14]  Igor A. Levandovskiy,et al.  Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25. , 2019, European journal of medicinal chemistry.

[15]  Dongwei Kang,et al.  Identification of highly potent and selective Cdc25 protein phosphatases inhibitors from miniaturization click-chemistry-based combinatorial libraries. , 2019, European journal of medicinal chemistry.

[16]  A. Lavecchia,et al.  Discovery of Novel Naphthylphenylketone and Naphthylphenylamine Derivatives as Cell Division Cycle 25B (CDC25B) Phosphatase Inhibitors: Design, Synthesis, Inhibition Mechanism and in Vitro Efficacy against Melanoma Cell Lines. , 2019, Journal of medicinal chemistry.

[17]  Patrick W V Butler,et al.  The Synthesis of Quinoline-based Tin Complexes with Pendant Schiff Bases , 2019, Zeitschrift für anorganische und allgemeine Chemie.

[18]  S. Ferrari,et al.  Pharmacophore-guided discovery of CDC25 inhibitors causing cell cycle arrest and tumor regression , 2019, Scientific Reports.

[19]  D M Parkin,et al.  Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods , 2018, International journal of cancer.

[20]  B. Glimelius,et al.  Recurrence Risk After Up-to-Date Colon Cancer Staging, Surgery, and Pathology: Analysis of the Entire Swedish Population , 2018, Diseases of the colon and rectum.

[21]  Zhe Jiang,et al.  CDC25 as a common therapeutic target for triple-negative breast cancer - the challenges ahead , 2018, Molecular & cellular oncology.

[22]  Gary D Bader,et al.  Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer , 2018, Cell reports.

[23]  Wenguang Liu,et al.  SIRT6 inhibits colorectal cancer stem cell proliferation by targeting CDC25A. , 2018, Oncology letters.

[24]  Anil K. Shukla,et al.  Activity-Based Probes for Isoenzyme- and Site-Specific Functional Characterization of Glutathione S-Transferases. , 2017, Journal of the American Chemical Society.

[25]  G. Kirsch,et al.  2-(Thienothiazolylimino)-1,3-thiazolidin-4-ones inhibit cell division cycle 25 A phosphatase. , 2016, Bioorganic & medicinal chemistry.

[26]  D. Agrawal,et al.  Phosphatases and kinases regulating CDC25 activity in the cell cycle: clinical implications of CDC25 overexpression and potential treatment strategies , 2016, Molecular and Cellular Biochemistry.

[27]  William A. Hammond,et al.  Pharmacologic resistance in colorectal cancer: a review , 2016, Therapeutic advances in medical oncology.

[28]  T. Hansen,et al.  Risk of recurrence in patients with colon cancer stage II and III: A systematic review and meta-analysis of recent literature , 2015, Acta oncologica.

[29]  David Shum,et al.  Small-Molecule Inhibitors of SETD8 with Cellular Activity , 2014, ACS chemical biology.

[30]  J. Kim,et al.  Novel anti-inflammatory function of NSC95397 by the suppression of multiple kinases. , 2014, Biochemical pharmacology.

[31]  Linda Z. Shi,et al.  The Interaction of CtIP and Nbs1 Connects CDK and ATM to Regulate HR–Mediated Double-Strand Break Repair , 2013, PLoS genetics.

[32]  C. Scott,et al.  Arylstibonic acids are potent and isoform-selective inhibitors of Cdc25a and Cdc25b phosphatases. , 2012, Bioorganic & medicinal chemistry.

[33]  Danny Reinberg,et al.  PR-Set7 and H4K20me1: at the crossroads of genome integrity, cell cycle, chromosome condensation, and transcription. , 2012, Genes & development.

[34]  C. G. Newton,et al.  The anti-cancer, anti-inflammatory and tuberculostatic activities of a series of 6,7-substituted-5,8-quinolinequinones. , 2010, Bioorganic & Medicinal Chemistry.

[35]  M. Barbacid,et al.  Overall Cdk activity modulates the DNA damage response in mammalian cells , 2009, The Journal of cell biology.

[36]  Zhenghe Wang,et al.  microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. , 2009, Cancer research.

[37]  R. Medema,et al.  The decision to enter mitosis: feedback and redundancy in the mitotic entry network , 2009, The Journal of cell biology.

[38]  Stephen P. Jackson,et al.  Human CtIP Mediates Cell Cycle Control of DNA End Resection and Double Strand Break Repair*S⃞ , 2009, Journal of Biological Chemistry.

[39]  N. Gresh,et al.  Novel naphthoquinone and quinolinedione inhibitors of CDC25 phosphatase activity with antiproliferative properties. , 2008, Bioorganic & medicinal chemistry.

[40]  Bernard Ducommun,et al.  CDC25 phosphatases in cancer cells: key players? Good targets? , 2007, Nature Reviews Cancer.

[41]  K. Shimizu,et al.  Prognostic significance of CDC25B expression in gliomas , 2006, Journal of Clinical Pathology.

[42]  M. Montès,et al.  Design, synthesis, and biological evaluation of novel naphthoquinone derivatives with CDC25 phosphatase inhibitory activity. , 2005, Bioorganic & medicinal chemistry.

[43]  M. Ittmann,et al.  Increased Expression and Activity of CDC25C Phosphatase and an Alternatively Spliced Variant in Prostate Cancer , 2005, Clinical Cancer Research.

[44]  M. Kupiec,et al.  The CDK regulates repair of double‐strand breaks by homologous recombination during the cell cycle , 2004, The EMBO journal.

[45]  J. Rudolph,et al.  Cdc25 phosphatases and cancer. , 2004, Chemistry & biology.

[46]  C. Tournigand,et al.  FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  J. Lazo,et al.  Dual G1 and G2 Phase Inhibition by a Novel, Selective Cdc25 Inhibitor 7-Chloro-6-(2-morpholin-4-ylethylamino)- quinoline-5,8-dione* , 2002, The Journal of Biological Chemistry.

[48]  D. Reinberg,et al.  Mitotic-specific methylation of histone H4 Lys 20 follows increased PR-Set7 expression and its localization to mitotic chromosomes. , 2002, Genes & development.

[49]  Peter Wipf,et al.  Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors. , 2002, Molecular pharmacology.

[50]  P. Wipf,et al.  Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25. , 2001, Journal of medicinal chemistry.

[51]  E. Campo,et al.  Differential Expression of cdc25 Cell-Cycle–Activating Phosphatases in Human Colorectal Carcinoma , 2001, Laboratory Investigation.

[52]  D. Chi,et al.  The regioselectivity in the reaction of 6,7-dihaloquinoline-5,8-diones with amine nucleophiles in various solvents , 2000 .

[53]  M. Loda,et al.  Role of the Cdc25A phosphatase in human breast cancer. , 2000, The Journal of clinical investigation.

[54]  M Monden,et al.  Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma. , 2000, Cancer research.

[55]  J. Kerns,et al.  Cdc25 inhibition and cell cycle arrest by a synthetic thioalkyl vitamin K analogue. , 2000, Cancer research.

[56]  H. Yokozaki,et al.  Overexpression of Cyclin‐dependent Kinase‐activating CDC25B Phosphatase in Human Gastric Carcinomas , 1997, Japanese journal of cancer research : Gann.

[57]  A. Grollman,et al.  Streptonigrin. 1. Structure-activity relationships among simple bicyclic analogues. Rate dependence of DNA degradation on quinone reduction potential. , 1986, Journal of medicinal chemistry.

[58]  C. Brezden-Masley,et al.  Current practices and challenges of adjuvant chemotherapy in patients with colorectal cancer. , 2014, Surgical oncology clinics of North America.

[59]  I. Hoffmann,et al.  Cell cycle regulation by the Cdc25 phosphatase family. , 2000, Progress in cell cycle research.